Vista Therapeutics People

VISTA PRINCIPALS
Spencer Farr, Ph.D., CEO & Chairman Founder and CEO of Xenometrix Inc. and Phase-1 Molecular Toxicology Experienced startup founder and CEO Charles Lieber, Ph.D., Chief Scientific Officer, SAB Chair Founder of Nanosys, Inc., one of the pioneer companies in nanotechnology Recognized world leader in nanotechnology, Distinguished Professor Harvard Chris Taylor, MD, Chief Medical Officer Professor of Neurosurgery, UNM Medical Center Noah Clay, Ph.D. Director of Harvard Center for Nanoscale Sciences Cedric Francois, MD, Ph.D. CEO Potentia Pharmaceuticals, expert on organ failure Charles Call, Ph.D. CEO MesoSystems, ICX, Ph.D. in Mechanical Engineering John Elling, Ph.D. Founder of Acoustic Cytometry Systems, experienced tech entrepreneur Sam Hicken, Ph.D. Director of Informatics at Phase-1, specialist in bioinformatics data/software		The Founders of Vista Therapeutics are Charles Lieber, Spencer Farr, and Harvard University. Professor Charles Lieber, Ph.D. of the Harvard Chemistry Department, is widely held as the foremost pioneer in the development of nanowires and applications thereto. He is the patented inventor of most of the core inventions that enable nanowires. Spencer Farr, Ph.D. is known throughout the toxicology and drug development communities as one of the most innovative thinkers in the field. He patented and pioneered much of the early work in gene expression related to drug safety. He was a professor of molecular toxicology at Harvard and MIT and was the founder of Xenometrix and Phase-1 Toxicology, Inc.